Proposed Rules


The Drug Enforcement Administration has reviewed and evaluated the petition in order to determine whether the data contained in the petition are sufficient to justify the initiation of the requested proceedings.

Based upon the investigations of the Drug Enforcement Administration and upon the scientific and medical evaluations and recommendation of the Secretary of Health, Education, and Welfare, received pursuant to Section 201(n) of the Act, the Administrator of the Drug Enforcement Administration finds that dextrophan does not have sufficient potential for abuse or abuse liability to justify its continued control in any schedule under the Act.

Therefor, under the authority vested in the Attorney General by Section 201(a) of the Act (21 U.S.C. 811(a)), and delegated to the Administrator of the Drug Enforcement Administration by regulations of the Department of Justice (28 CFR part O), the Administrator hereby proposes that CFR 1308.11(b) be amended as follows:

§ 1308.11 Schedule I

[Table of compounds]

(b) Opiates—Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and others, whenever the existence of such isomers, esters, ethers, salts, and other derivatives is possible, within the specific chemical designation:

[Table of compounds]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[21 CFR Part 1308 ]

DEXTROPHAN

Removal From Schedule I of Schedules of Controlled Substances

Dextrophan is a controlled substance listed in Schedule I of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 812(c) Schedule I (a) 13); §1308.11(b) (13), Title 21 of the Code of Federal Regulations (CFR).

On November 14, 1974, the Drug Enforcement Administration received a petition for the initiation of proceedings to remove dextrophan from control under the Act. The petitioner is Hofman-LaRoche, Inc.

By a letter dated November 20, 1974, the Drug Enforcement Administration notified Hofman-LaRoche, Inc., that the above petition has been accepted for filing in accordance with 21 CFR 1308.44(c). Notice of acceptance for filing of this petition was published in the Federal Register, Vol. 39, No. 237, Monday, December 9, 1974.

All interested persons are invited to submit their comments or objections to this proposal which present reasonable grounds for this rule not to be finalized and requests a hearing in accordance with 21 CFR 1308.45, the party will be notified by registered mail of the time and place that the hearing will be held. If objections are submitted do not present such reasonable grounds, the party will be so advised by registered mail.

If no objections presenting grounds for a hearing on the proposal are received within the time limitations, all interested parties waive or are deemed to waive their opportunity for a hearing or to participate in a hearing, the Administrator, after giving consideration to written comments and objections, will issue his final order pursuant to 21 CFR 1308.48 without a hearing.

Dated: April 8, 1976.

JERRY N. JENSEN, Deputy Administrator, Drug Enforcement Administration.

[21 CFR Part 1311 ]

CONTROLLED SUBSTANCES

Registration of Importers and Exporters: Correction

In FR Doc. 76-9564 appearing at page 14599 in the Federal Register of April 5, 1976, paragraph (a) of §1311.42 appearing on page 14406 is corrected in the tenth line of that paragraph by adding the number "(c)" immediately following the letter "(c)" and immediately before the number "(D)".

The time period for filing comments, objections and requests for hearing is extended to May 25, 1976.


PETER B. BICKNEX, Administrator, Drug Enforcement Administration.

[FR Doc. 76-11229 Filed 4-16-76; 8:45 am]